Traditional blood filter manufacturing uses solvent-based hydrophilization, consuming large volumes of water, generating chemical wastewater, and emitting significant carbon. TTRI's SCF Process replaces solvents with supercritical carbon dioxide, achieving hydrophilization through physical implantation under fully anhydrous, solvent-free conditions-a fundamental shift from chemical treatment.  carbon dioxide is captured from the atmosphere and recycled in a closed loop with zero net emissions, eliminating all solvent use and wastewater generation. Per-unit cost drops by 57% and carbon emissions fall by over 80%. With global demand of approximately 120 million units per year, this technology creates substantial industrial value. Products are currently under quality verification at Taiwan Blood Donation Center.